ProCE Banner Activity

CE / CME

Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Video

On-demand webcast of expert faculty presentation and case discussion on precision therapeutic strategies to treat patients with NF1-associated tumors—improving outcomes through use of targeted MEK inhibition.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: December 24, 2024

Expiration: June 23, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.

Alexion Pharmaceuticals

SpringWorks Therapeutics, Inc.

Target Audience

This educational activity is intended for medical oncologists, neurologists, neuro-oncologists, pediatric neuro-oncologists, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with NF1-associated tumors.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Neurofibromatosis.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Evaluate the genetic mutations and molecular pathways involved in the development of NF1-associated tumors and their implications for targeted therapy

  • Incorporate MEK inhibitors into treatment plans for patients with NF1-associated plexiform neurofibromas based on the latest evidence, recommendations, and individual patient and tumor characteristics

  • Formulate supportive care strategies for the long-term management of patients with NF1, considering the chronic nature of the disease, toxicity management, surveillance for malignant transformation, and quality of life issues

  • Evaluate available clinical evidence and potential expanded indications for emerging targeted agents in NF1 to prepare for efficient integration of emerging therapies into clinical practice

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jaishri Blakeley, MD

The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Director, The Neurofibromatosis Therapeutic Acceleration Program
Director, the Johns Hopkins Comprehensive Neurofibromatosis Program
Professor of Neurology, Neurosurgery and Oncology
The Johns Hopkins School of Medicine
Baltimore, Maryland

Jaishri Blakeley, MD: consultant/advisor/speaker: Alexion, SpringWorks; researcher: Bristol Myers Squibb.

Miriam Bornhorst, MD

Neuro-Oncologist
Max Lacewell Endowed Brain Tumor Research Scholar
NF-Oncology
Ann & Robert H. Lurie Children’s Hospital
Stanley Manne Children’s Research Institute
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Miriam Bornhorst, MD: consultant/advisor/speaker: Alexion.

Michael J. Fisher, MD

Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Center for Childhood Cancer Research and Division of Oncology
The Children’s Hospital of Philadelphia
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Michael J. Fisher, MD: consultant/advisor/speaker: AstraZeneca, Day One, SpringWorks; researcher: Array BioPharma, AstraZeneca, Exelixis.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, RNP, AOCNP, as noted below.​

Kristi K. Orbaugh, MSN, RNP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daichii Sankyo, Eli Lilly, Gilead, Pfizer, Regeneron, SOBI.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 24, 2024, through June 23, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-346-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 23, 2025. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.